Coronary embolism in a patient with mitral valve prosthesis： successful management with tirofiban and half-dose tissue-type plasminogen activator

Coronary embolism has been considered as a rare cause of coronary occlusion. Prosthetic heart valve is an infrequent cause of this condition. The exact incidence of coronary embolization in patients with prosthetic heart valves is not well known. Furthermore, the effective treatment and management o...

Full description

Saved in:
Bibliographic Details
Published in:Chinese medical journal 2007-12, Vol.120 (24), p.2321-2322
Main Authors: Atmaca, Yusuf, Ozdol, Cagdas, Erol, Cetin
Format: Article
Language:English
Subjects:
Coronary Thrombosis - drug therapy
Coronary Thrombosis - etiology
Embolism - drug therapy
Embolism - etiology
Heart Valve Prosthesis - adverse effects
Humans
Male
Middle Aged
Mitral Valve - surgery
Tissue Plasminogen Activator - administration & dosage
Tyrosine - administration & dosage
Tyrosine - analogs & derivatives
二尖瓣修复术
冠状动脉栓塞
心脏病
血纤维蛋白溶酶原
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c421t-7d573debc5cd48a488c29c2ce219d34ee750be3969729b44db985e0e39828fc13
cites cdi_FETCH-LOGICAL-c421t-7d573debc5cd48a488c29c2ce219d34ee750be3969729b44db985e0e39828fc13
container_end_page 2322
container_issue 24
container_start_page 2321
container_title Chinese medical journal
container_volume 120
creator Atmaca, Yusuf
Ozdol, Cagdas
Erol, Cetin
description Coronary embolism has been considered as a rare cause of coronary occlusion. Prosthetic heart valve is an infrequent cause of this condition. The exact incidence of coronary embolization in patients with prosthetic heart valves is not well known. Furthermore, the effective treatment and management of coronary emboli in this setting remains unknown. It is the purpose of this paper to report the successful management of a case of coronary embolism with half-dose tissue-type plasminogen activator （tPA） and tirofiban given intravenously in a patient with initial valve prosthesis.
doi_str_mv 10.1097/00029330-200712020-00033
format article
fullrecord <record><control><sourceid>wanfang_jour_proqu</sourceid><recordid>TN_cdi_wanfang_journals_zhcmj200724033</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cqvip_id>26234737</cqvip_id><wanfj_id>zhcmj200724033</wanfj_id><sourcerecordid>zhcmj200724033</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-7d573debc5cd48a488c29c2ce219d34ee750be3969729b44db985e0e39828fc13</originalsourceid><addsrcrecordid>eNpFUUuO1DAUtBCIaQaugCwW7AL-JY6XqMVPGokNrC3Heem48acndno0XIMdZ-FOXAE308ysnlSqqvdeFUKYkjeUKPmWEMIU56RhhEjKCCNNhTh_hDasFaxpO0Efow3hXdd0SqkL9CznfRW1reyeogva004yJjfo5zYtKZrlFkMYknc5YBexwQdTHMSCb1yZcXBlMR4fjT8CPiwplxmyy39-_8J5tRZynlaPg4lmB-FeVdySJjeYahdHPBs_NWPKUPGcV2jK7aGaeZODi2kHlWWLO5qSlufoyWR8hhfneYm-fXj_dfupufry8fP23VVjBaOlkWMr-QiDbe0oeiP63jJlmQVG1cgFgGzJAFx1SjI1CDEOqm-BVKRn_WQpv0Sv73xvTJxM3Ol9WpdYN-ofsw37U7ZM1FQfiPX36xVy0cFlC96bCGnNulNEMSlPjv0d0daQ8gKTPiwu1HQ1JfrUnP7fnL5vTv9rrkpfnnesQ4DxQXiuqhJenb3nFHfXrt47GPt9ch406xgXkkv-F2buo9w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69092771</pqid></control><display><type>article</type><title>Coronary embolism in a patient with mitral valve prosthesis： successful management with tirofiban and half-dose tissue-type plasminogen activator</title><source>HEAL-Link subscriptions: Lippincott Williams &amp; Wilkins</source><creator>Atmaca, Yusuf ; Ozdol, Cagdas ; Erol, Cetin</creator><creatorcontrib>Atmaca, Yusuf ; Ozdol, Cagdas ; Erol, Cetin</creatorcontrib><description>Coronary embolism has been considered as a rare cause of coronary occlusion. Prosthetic heart valve is an infrequent cause of this condition. The exact incidence of coronary embolization in patients with prosthetic heart valves is not well known. Furthermore, the effective treatment and management of coronary emboli in this setting remains unknown. It is the purpose of this paper to report the successful management of a case of coronary embolism with half-dose tissue-type plasminogen activator （tPA） and tirofiban given intravenously in a patient with initial valve prosthesis.</description><identifier>ISSN: 0366-6999</identifier><identifier>EISSN: 2542-5641</identifier><identifier>DOI: 10.1097/00029330-200712020-00033</identifier><identifier>PMID: 18167227</identifier><language>eng</language><publisher>China: Department of Cardiology,Ankara University Faculty of Medicine,06530 Karakusunlar,Ankara,Turkey</publisher><subject>Coronary Thrombosis - drug therapy ; Coronary Thrombosis - etiology ; Embolism - drug therapy ; Embolism - etiology ; Heart Valve Prosthesis - adverse effects ; Humans ; Male ; Middle Aged ; Mitral Valve - surgery ; Tissue Plasminogen Activator - administration &amp; dosage ; Tyrosine - administration &amp; dosage ; Tyrosine - analogs &amp; derivatives ; 二尖瓣修复术 ; 冠状动脉栓塞 ; 心脏病 ; 血纤维蛋白溶酶原</subject><ispartof>Chinese medical journal, 2007-12, Vol.120 (24), p.2321-2322</ispartof><rights>Copyright © Wanfang Data Co. Ltd. All Rights Reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-7d573debc5cd48a488c29c2ce219d34ee750be3969729b44db985e0e39828fc13</citedby><cites>FETCH-LOGICAL-c421t-7d573debc5cd48a488c29c2ce219d34ee750be3969729b44db985e0e39828fc13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://image.cqvip.com/vip1000/qk/85656X/85656X.jpg</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18167227$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Atmaca, Yusuf</creatorcontrib><creatorcontrib>Ozdol, Cagdas</creatorcontrib><creatorcontrib>Erol, Cetin</creatorcontrib><title>Coronary embolism in a patient with mitral valve prosthesis： successful management with tirofiban and half-dose tissue-type plasminogen activator</title><title>Chinese medical journal</title><addtitle>Chinese Medical Journal</addtitle><description>Coronary embolism has been considered as a rare cause of coronary occlusion. Prosthetic heart valve is an infrequent cause of this condition. The exact incidence of coronary embolization in patients with prosthetic heart valves is not well known. Furthermore, the effective treatment and management of coronary emboli in this setting remains unknown. It is the purpose of this paper to report the successful management of a case of coronary embolism with half-dose tissue-type plasminogen activator （tPA） and tirofiban given intravenously in a patient with initial valve prosthesis.</description><subject>Coronary Thrombosis - drug therapy</subject><subject>Coronary Thrombosis - etiology</subject><subject>Embolism - drug therapy</subject><subject>Embolism - etiology</subject><subject>Heart Valve Prosthesis - adverse effects</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mitral Valve - surgery</subject><subject>Tissue Plasminogen Activator - administration &amp; dosage</subject><subject>Tyrosine - administration &amp; dosage</subject><subject>Tyrosine - analogs &amp; derivatives</subject><subject>二尖瓣修复术</subject><subject>冠状动脉栓塞</subject><subject>心脏病</subject><subject>血纤维蛋白溶酶原</subject><issn>0366-6999</issn><issn>2542-5641</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNpFUUuO1DAUtBCIaQaugCwW7AL-JY6XqMVPGokNrC3Heem48acndno0XIMdZ-FOXAE308ysnlSqqvdeFUKYkjeUKPmWEMIU56RhhEjKCCNNhTh_hDasFaxpO0Efow3hXdd0SqkL9CznfRW1reyeogva004yJjfo5zYtKZrlFkMYknc5YBexwQdTHMSCb1yZcXBlMR4fjT8CPiwplxmyy39-_8J5tRZynlaPg4lmB-FeVdySJjeYahdHPBs_NWPKUPGcV2jK7aGaeZODi2kHlWWLO5qSlufoyWR8hhfneYm-fXj_dfupufry8fP23VVjBaOlkWMr-QiDbe0oeiP63jJlmQVG1cgFgGzJAFx1SjI1CDEOqm-BVKRn_WQpv0Sv73xvTJxM3Ol9WpdYN-ofsw37U7ZM1FQfiPX36xVy0cFlC96bCGnNulNEMSlPjv0d0daQ8gKTPiwu1HQ1JfrUnP7fnL5vTv9rrkpfnnesQ4DxQXiuqhJenb3nFHfXrt47GPt9ch406xgXkkv-F2buo9w</recordid><startdate>20071220</startdate><enddate>20071220</enddate><creator>Atmaca, Yusuf</creator><creator>Ozdol, Cagdas</creator><creator>Erol, Cetin</creator><general>Department of Cardiology,Ankara University Faculty of Medicine,06530 Karakusunlar,Ankara,Turkey</general><scope>2RA</scope><scope>92L</scope><scope>CQIGP</scope><scope>W91</scope><scope>~WA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>2B.</scope><scope>4A8</scope><scope>92I</scope><scope>93N</scope><scope>PSX</scope><scope>TCJ</scope></search><sort><creationdate>20071220</creationdate><title>Coronary embolism in a patient with mitral valve prosthesis： successful management with tirofiban and half-dose tissue-type plasminogen activator</title><author>Atmaca, Yusuf ; Ozdol, Cagdas ; Erol, Cetin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-7d573debc5cd48a488c29c2ce219d34ee750be3969729b44db985e0e39828fc13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Coronary Thrombosis - drug therapy</topic><topic>Coronary Thrombosis - etiology</topic><topic>Embolism - drug therapy</topic><topic>Embolism - etiology</topic><topic>Heart Valve Prosthesis - adverse effects</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mitral Valve - surgery</topic><topic>Tissue Plasminogen Activator - administration &amp; dosage</topic><topic>Tyrosine - administration &amp; dosage</topic><topic>Tyrosine - analogs &amp; derivatives</topic><topic>二尖瓣修复术</topic><topic>冠状动脉栓塞</topic><topic>心脏病</topic><topic>血纤维蛋白溶酶原</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Atmaca, Yusuf</creatorcontrib><creatorcontrib>Ozdol, Cagdas</creatorcontrib><creatorcontrib>Erol, Cetin</creatorcontrib><collection>维普_期刊</collection><collection>中文科技期刊数据库-CALIS站点</collection><collection>中文科技期刊数据库-7.0平台</collection><collection>中文科技期刊数据库-医药卫生</collection><collection>中文科技期刊数据库- 镜像站点</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Wanfang Data Journals - Hong Kong</collection><collection>WANFANG Data Centre</collection><collection>Wanfang Data Journals</collection><collection>万方数据期刊 - 香港版</collection><collection>China Online Journals (COJ)</collection><collection>China Online Journals (COJ)</collection><jtitle>Chinese medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Atmaca, Yusuf</au><au>Ozdol, Cagdas</au><au>Erol, Cetin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Coronary embolism in a patient with mitral valve prosthesis： successful management with tirofiban and half-dose tissue-type plasminogen activator</atitle><jtitle>Chinese medical journal</jtitle><addtitle>Chinese Medical Journal</addtitle><date>2007-12-20</date><risdate>2007</risdate><volume>120</volume><issue>24</issue><spage>2321</spage><epage>2322</epage><pages>2321-2322</pages><issn>0366-6999</issn><eissn>2542-5641</eissn><notes>mitral valve prosthesis; coronary embolism; tirofiban</notes><notes>R654.2</notes><notes>mitral valve prosthesis</notes><notes>coronary embolism</notes><notes>tirofiban</notes><notes>11-2154/R</notes><notes>ObjectType-Case Study-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-4</notes><notes>content type line 23</notes><notes>ObjectType-Report-1</notes><notes>ObjectType-Article-3</notes><abstract>Coronary embolism has been considered as a rare cause of coronary occlusion. Prosthetic heart valve is an infrequent cause of this condition. The exact incidence of coronary embolization in patients with prosthetic heart valves is not well known. Furthermore, the effective treatment and management of coronary emboli in this setting remains unknown. It is the purpose of this paper to report the successful management of a case of coronary embolism with half-dose tissue-type plasminogen activator （tPA） and tirofiban given intravenously in a patient with initial valve prosthesis.</abstract><cop>China</cop><pub>Department of Cardiology,Ankara University Faculty of Medicine,06530 Karakusunlar,Ankara,Turkey</pub><pmid>18167227</pmid><doi>10.1097/00029330-200712020-00033</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0366-6999
ispartof Chinese medical journal, 2007-12, Vol.120 (24), p.2321-2322
issn 0366-6999
2542-5641
language eng
recordid cdi_wanfang_journals_zhcmj200724033
source HEAL-Link subscriptions: Lippincott Williams & Wilkins
subjects Coronary Thrombosis - drug therapy
Coronary Thrombosis - etiology
Embolism - drug therapy
Embolism - etiology
Heart Valve Prosthesis - adverse effects
Humans
Male
Middle Aged
Mitral Valve - surgery
Tissue Plasminogen Activator - administration & dosage
Tyrosine - administration & dosage
Tyrosine - analogs & derivatives
二尖瓣修复术
冠状动脉栓塞
心脏病
血纤维蛋白溶酶原
title Coronary embolism in a patient with mitral valve prosthesis： successful management with tirofiban and half-dose tissue-type plasminogen activator
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T21%3A28%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wanfang_jour_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Coronary%20embolism%20in%20a%20patient%20with%20mitral%20valve%20prosthesis%EF%BC%9A%20successful%20management%20with%20tirofiban%20and%20half-dose%20tissue-type%20plasminogen%20activator&rft.jtitle=Chinese%20medical%20journal&rft.au=Atmaca,%20Yusuf&rft.date=2007-12-20&rft.volume=120&rft.issue=24&rft.spage=2321&rft.epage=2322&rft.pages=2321-2322&rft.issn=0366-6999&rft.eissn=2542-5641&rft_id=info:doi/10.1097/00029330-200712020-00033&rft_dat=%3Cwanfang_jour_proqu%3Ezhcmj200724033%3C/wanfang_jour_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c421t-7d573debc5cd48a488c29c2ce219d34ee750be3969729b44db985e0e39828fc13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=69092771&rft_id=info:pmid/18167227&rft_cqvip_id=26234737&rft_wanfj_id=zhcmj200724033&rfr_iscdi=true